Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

TELESTA THERAPEUTICS INC T.TST

Healthcare Biotechnology
"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."


TSX:TST - Post by User

TELESTA THERAPEUTICS INC > Ipsen hires David Meek as CEO
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by finetimetoleaveon Jul 11, 2016 3:52pm
353 Views
Post# 25042204

RE:RE:Ipsen hires David Meek as CEO

RE:RE:Ipsen hires David Meek as CEObettiing they aren't paying out to tst for the rights on the product- cheaper to buy them out and signed a deal - just what that amount is a question mark
i would say as a good guess tst took the offer and we wait for the anouncement
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities